COVID-19: Vaccines and Therapeutics

Feb 18, 2021
Effective cybersecurity is needed more than ever before. As the number of computers and digital data have grown, so has the sophistication of attacks that target these assets.      
Feb 18, 2021
Proin rhoncus ac quam laoreet dignissim. Fusce et malesuada nulla. Nullam nec sodales velit. Proin facilisis aliquam varius. Vivamus et tellus eget mi aliquam eleifend.
Feb 12, 2021
The departments of Health and Human Services and Defense ordered 200 million more doses of COVID-19 vaccines authorized for emergency use, half from Pfizer for $2 billion and the rest from Moderna for about $1.7 billion.
Feb 12, 2021
The nation’s COVID-19 vaccination effort continues to have challenges, and we are committed to working with all stakeholders to make it as effective as possible to protect our patients and communities.
Feb 11, 2021
During an AHA virtual briefing for lawmakers and staff, leaders from three health systems – Trinity Health, Ascension and LifePoint Health, which serve communities all across the country – today shared their organizations’ experiences with COVID-19 vaccinations, as well as recommendations to…
Feb 10, 2021
The Food and Drug Administration authorized administering the monoclonal antibodies bamlanivimab and etesevimab together to treat patients 12 and older with mild-to-moderate COVID-19 who are at high risk for progressing to severe disease but not hospitalized or on oxygen therapy.
Feb 9, 2021
An estimated 68% of U.S. adults intended to receive a COVID-19 vaccine when surveyed by the Centers for Disease Control and Prevention in December, up from 61.9% in September.
Feb 8, 2021
Congress is discussing another COVID-19 relief package, one that would use its reconciliation process to approve legislation that could spur the nation’s health and economic recoveries from the ongoing pandemic. The following resources will aid AHA members’ efforts to advocate on behalf of…
Feb 8, 2021
The Food and Drug Administration revised and reissued its emergency use authorization for COVID-19 convalescent plasma to treat hospitalized patients with COVID-19.
Feb 5, 2021
The Food and Drug Administration cautioned health care providers against using compounded remdesivir drug products due to the potential for patient exposure to substandard or adulterated products.